When to Give Venofer (Iron Sucrose)
Venofer should be administered for iron deficiency anemia in chronic kidney disease patients, and as first-line therapy in inflammatory bowel disease patients with active disease, hemoglobin <10 g/dL, oral iron intolerance, or need for ESAs.
Primary Indications by Disease State
Chronic Kidney Disease (CKD)
Venofer is FDA-approved specifically for iron deficiency anemia in CKD patients 1. The KDIGO 2026 guidelines provide the most current framework 2:
Hemodialysis-dependent CKD (HDD-CKD):
- Administer 100 mg IV per hemodialysis session (early in session, within first hour)
- Total treatment course: 1000 mg
- Dosing: Either undiluted over 2-5 minutes or diluted in 100 mL normal saline over ≥15 minutes 1
Non-dialysis dependent CKD (NDD-CKD):
- 200 mg IV on 5 occasions over 14 days
- Alternative: 500 mg infusions on Day 1 and Day 14 (diluted in 250 mL normal saline over 3.5-4 hours) 1
Peritoneal dialysis-dependent CKD (PDD-CKD):
- Three divided doses over 28 days: 300 mg over 1.5 hours (Day 1), 300 mg over 1.5 hours (Day 15), 400 mg over 2.5 hours (Day 29) 1
Inflammatory Bowel Disease (IBD)
The 2015 ECCO guidelines establish clear first-line indications 3:
Mandatory IV iron situations:
- Clinically active IBD
- Previous oral iron intolerance
- Hemoglobin <10 g/dL
- Patients requiring erythropoiesis-stimulating agents
Dosing by hemoglobin and weight:
- Hb 10-12 g/dL (women) or 10-13 g/dL (men): 1000 mg if <70 kg, 1500 mg if ≥70 kg
- Hb 7-10 g/dL: 1500 mg if <70 kg, 2000 mg if ≥70 kg 3
Important caveat: While ferric carboxymaltose is preferred in IBD due to higher single-dose capacity (up to 1000 mg vs. 200 mg for iron sucrose), iron sucrose remains effective but requires multiple visits—typically 200-300 mg per treatment episode 3.
Other Validated Indications
Restless Legs Syndrome: The 2026 Mayo Clinic algorithm recommends IV iron when 4:
- Serum ferritin 75-300 μg/L with TSAT <45%, OR
- Serum ferritin <75 μg/L with TSAT <45% AND oral iron has failed/not tolerated/GI disease prevents absorption/severe RLS requiring rapid response
Pregnancy-related anemia:
- Second and third trimester with Hb <9 g/dL
- Optimal timing: <34 weeks gestation with ≥6 weeks latency before delivery
- Doses ≥800 mg show superior outcomes (Hb increase 2.6-3.1 g/dL) 5
- Standard regimen: Three 200 mg doses on consecutive days 6, 7
Heart Failure with reduced ejection fraction:
- LVEF ≤40% with iron deficiency (ferritin <100 ng/mL OR ferritin 100-299 ng/mL with TSAT <20%)
- Improves quality of life and corrects iron stores 8
When NOT to Use Venofer
Absolute contraindications:
Relative contraindications/cautions:
- Active systemic infection (temporarily suspend) 2
- Transferrin saturation >50% and ferritin >800 μg/L in IBD patients 3
Dosing Limitations Specific to Iron Sucrose
Unlike newer formulations, iron sucrose has strict maximum single-dose limits 2, 9:
- Maximum single dose: 200 mg (CKD patients)
- Maximum single dose: 400 mg (PD patients only)
- Minimum infusion time: 15 minutes for maximum dose 2
This limitation means iron sucrose requires multiple patient visits to deliver total iron repletion doses of 1000+ mg, making it less convenient than ferric carboxymaltose (1000 mg single dose) or ferric derisomaltose (up to 20 mg/kg single dose) 2, 9.
Monitoring and Retreatment
Timing of laboratory assessment:
- Do NOT check iron parameters within 4 weeks of last infusion (circulating iron interferes with assays) 10
- Check CBC and iron parameters 4-8 weeks post-treatment 10
- CKD patients: Every 1-3 months for dialysis patients, every 3 months for non-dialysis 2
Expected response:
- Hemoglobin should increase 1-2 g/dL within 4-8 weeks 10
- IBD patients: ≥2 g/dL increase within 4 weeks is acceptable 3
Retreatment criteria:
- When iron deficiency recurs (document with ferritin and TSAT) 1
- Maintenance dosing in hemodialysis: 0.5 mg/kg every 2 weeks for pediatrics 1
Safety Considerations
Hypersensitivity risk:
- Serious reactions including anaphylaxis can occur but are rare (<0.1%) 11
- Monitor patients for ≥30 minutes after infusion 1
- Resuscitation facilities must be available 12
- No test dose required for iron sucrose (unlike iron dextran) 3, 2
Hypophosphatemia: Iron sucrose has significantly lower risk of hypophosphatemia compared to ferric carboxymaltose (2.3% vs. 47%) 11. This makes iron sucrose preferable for patients requiring repeated infusions.
Infusion reactions: Most adverse events are minor (nausea, injection site pain, mild hypotension) and occur in <13% of patients 13, 6. Serious adverse events are extremely rare with proper administration 13.
Practical Algorithm
- Confirm iron deficiency anemia (low Hb + low ferritin or TSAT <20%)
- Identify indication: CKD, active IBD, pregnancy, heart failure, or RLS
- Check contraindications: Known allergy, TSAT >45%, active infection
- Choose iron sucrose when:
- Patient has CKD (FDA-approved indication)
- Ferric carboxymaltose unavailable or contraindicated (need to avoid hypophosphatemia)
- Cost considerations favor iron sucrose
- Dose according to indication (see specific regimens above)
- Monitor during infusion for 30+ minutes
- Reassess 4-8 weeks post-treatment with CBC and iron studies
- Retreat if iron deficiency recurs